EMV Capital plc (AIM: EMVC), the London-headquartered deep tech and life sciences venture capital group, has announced that its portfolio company AMR Bio received official meeting minutes from a Type B End-of-Phase 2 meeting with the US Food and Drug Administration, in which the FDA expressed support for the proposed Phase 3 trial design for XF-73 Nasal. The milestone was achieved within approximately 14 months of AMR Bio's formation through EMVC's Venture Build programme. AMR Bio now plans to incorporate the FDA's recommendations and submit full Phase 3 protocols in the coming months, representing a material step forward for a product targeting pre-surgical infection prevention.
Key Points
- EMV Capital plc (AIM: EMVC) is a deep tech and life sciences VC investment group quoted on AIM
- Portfolio company AMR Bio received constructive FDA Type B EOP2 feedback supporting its XF-73 Nasal Phase 3 trial design
- EMVC holds a direct 29.7% interest in AMR Bio, formed in September 2025; XF-73 Nasal holds FDA QIDP designation, Fast Track status, and UK MHRA Innovation Passport
- Investors will be watching for submission of full Phase 3 protocols to the FDA and progress on AMR Bio's CMC and CRO strategy
XF-73 Nasal's Phase 2b Results and FDA-Supported Phase 3 Design
XF-73 Nasal is a first-in-class antimicrobial nasal gel designed for use in the 24 hours before surgery to reduce nasal burden of Staphylococcus aureus, including MRSA, thereby preventing post-operative surgical site infections. The FDA Type B meeting followed a previously reported successful Phase 2b clinical study in patients undergoing open-heart surgery, in which XF-73 achieved a 99.5% reduction in Staphylococcus aureus nasal carriage before surgery. The announcement states the FDA was supportive of the proposed Phase 3 design and provided recommendations that will inform the final protocol for two planned pivotal trials.
XF-73 Nasal's Regulatory Designations and Market Exclusivity Provisions
XF-73 Nasal holds Qualified Infectious Disease Product designation and Fast Track status from the FDA, which together provide an additional five years of US market exclusivity and eligibility for priority review and rolling submission. In the United Kingdom, the product has been granted an Innovation Passport under the MHRA's Innovative Licensing and Access Pathway. These designations are commercially significant, as they are designed to accelerate the regulatory pathway and extend the period of exclusivity available to the product upon potential approval, factors investors in clinical-stage biotechnology companies typically monitor closely.
AMR Bio's Formation Within EMVC's Venture Build Programme and Ownership Structure
AMR Bio was formed in September 2025 through EMVC's Venture Build programme, with the company stating this milestone was achieved within approximately 14 months of formation. EMVC holds a direct equity interest of 29.7% in AMR Bio, with further interests held by private investors through EMVC's EIS Syndicate and Fund. The announcement notes that since formation, AMR Bio has transferred a US Investigational New Drug application, secured ILAP status in the UK, and now received supportive FDA feedback on its Phase 3 design, all described by management as consistent with a capital-efficient development model.
AMR Bio's Next Steps Towards Phase 3 Submission and Commercialisation Strategy
Following receipt of FDA meeting minutes, AMR Bio will incorporate the regulator's recommendations into its clinical development plans and expects to submit full Phase 3 protocols to the FDA in the coming months. The announcement states the company's immediate priority also includes progressing its chemistry, manufacturing and controls strategy and its contract research organisation selection. AMR Bio is additionally seeking partners for final clinical studies and commercialisation. Investors may be watching the timing of protocol submission and any partnership announcements as near-term indicators of programme momentum.




Please wait processing your request...